TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

TG Therapeutics, Inc.NASDAQ: TGTX

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q3 FY2026 stock-based compensation of $24.7M rose 39.7% year over year, behind the +44.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 11.4% from the prior quarter. Over 3 fiscal years it compounded at +49.9% a year.

Context

  • Stock-based compensation amounted to 10.5% of revenue in FY2025, down 2.4 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +39.7% toward the trailing-twelve-month pace of +44.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$24.7M-11.4% QoQ
Last fiscal yearDec 2025
$64.67M+52.0% YoY
LTMSep 2026
$88.18M+44.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.7%——
1 year+52.0%——
3-year CAGR+49.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
64.67M USD
Year-over-year change
+52.0%
4-year CAGR
+1.4%

Stock-Based Compensation vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +44.6% is the 2nd highest of 7, against a peer median of +9.1%.
  • Stock-based compensation amounts to 9.8% of revenue for TGTX, versus a peer median of 37.2%.
TGTX Competitors
Stock-Based Compensation for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TGTXTG Therapeutics, Inc.LTM Sep 2026$88.18M USD+44.6%+49.9%9.8%
GMABGenmab A/SLTM Jun 2026$71M USD——1.7%
XNCRXencor, Inc.LTM Jun 2026$39.03M USD+10.2%-4.0%37.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$36.81M USD-0.7%—32869.6%
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M USD+26.4%-48.5%16.0%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
ADAGAdagene Inc.LTM Jun 2024$7.27M USD—-29.1%891.4%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M USD+88.8%+25.6%—
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
Peer median (excluding TGTX) —+9.1%-7.6%37.2%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(348.1M)(198.34M)12.67M23.38M447.18M
Depreciation & Amortization494K515K423K280K244K
Deferred Income Tax517K000(348M)
Stock-Based Compensation61.27M19.19M37.93M42.54M64.67M
Change in Working Capital(12.22M)(1.65M)(84.66M)(109.3M)(194.54M)
Accounts Receivables(1.39M)1.39M(51.09M)(78.09M)(176.44M)
Inventory(15.99M)0(36.94M)(66.85M)(33.45M)
Accounts Payables15.99M(11.01M)192K055.88M
Other Working Capital(10.83M)7.97M3.18M35.65M(40.52M)
Other Non-Cash Items2.4M4.11M2.22M2.58M5.67M
Operating Cash Flow(295.63M)(176.17M)(31.41M)(40.52M)(24.77M)
Capital Expenditures(401K)(14K)0(45K)(214K)
Acquisitions (Net)(69K)20M000
Purchases of Investments(55.53M)(107.27M)(146.88M)(311.89M)(223.49M)
Sales of Investments55.6M87.28M96.23M310.9M237.5M
Other Investing Activities69K(20M)000
Investing Cash Flow(332K)(20.01M)(50.65M)(1.04M)13.8M
Debt Repayment40M(975K)25M137.26M0
Common Stock Issued2.22M584K46.3M01.51M
Common Stock Repurchased000(8.76M)(91.24M)
Dividends Paid00000
Other Financing Activities(800K)01.41M25K0
Financing Cash Flow41.42M(391K)72.71M128.53M(89.73M)
Effect of Forex Changes00000
Net Change in Cash(254.55M)(196.57M)(9.36M)86.97M(100.7M)
Free Cash Flow(296.04M)(176.18M)(31.41M)(40.56M)(24.99M)

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.